Australia: The Future With The Medicines Australia Code Of Conduct

Last Updated: 17 September 2007
Article by Greg Williams and Zöe Kimberley

On 27 June 2007, the Australian Competition Tribunal handed down its judgment on the appeal by Medicines Australia against the ACCC's approval of the 15th edition of the Medicines Australia Code of Conduct. Medicines Australia had appealed against conditions imposed by the ACCC, requiring the disclosure by pharmaceutical companies of detailed information about the nature and extent of hospitality provided to health professionals at educational meetings and symposia.

Medicines Australia's appeal was entirely unsuccessful. The Tribunal has required Medicines Australia to amend the Code to insert provisions to substantially the same effect as the conditions imposed by the ACCC.

The Tribunal justified its decision on the grounds of the so-called "public benefit" test. The message was clear: in the Tribunal's view, benefits provided by pharmaceutical companies to healthcare professionals may affect their prescribing practices. Thus, such prescribing decisions may be "influenced by considerations not relevant to patient welfare". In the Tribunal's view, the Code is a mechanism which, although far from perfect, regulates and constrains the provision of benefits to healthcare professionals. The ACCC's conditions were said by the Tribunal to provide an appropriate incentive for compliance with the Code.

In this article we consider the reasoning behind the decision, and the implications for future marketing practices of pharmaceutical companies given the new disclosure rules.

The decision - in brief

The issue at the heart of the dispute between Medicines Australia and the ACCC was the imposition of the reporting conditions. While other issues were addressed, including the regulation of product information and the provision of starter packs to medical practitioners, these were side issues to the main dispute.

The conditions imposed on the approval, which the Tribunal has required Medicines Australia to incorporate into an amended version of the Code, require each member company to report to Medicines Australia with details about doctor-orientated functions and the associated budgets.1This information will be published on Medicines Australia's website and thus will be open to public scrutiny and constant monitoring by Medicines Australia.

Why reporting conditions?

The Tribunal's decision clearly seeks to increase the accountability of pharmaceutical companies and ensure that they are playing fair when it comes to entertaining and educating doctors.

The Tribunal decided that where appropriate, it could impose conditions to provide "an incentive to compliance [sic] with the Code provisions relating to the conferring of benefits on doctors". The Tribunal made it clear that it thought that, absent such an incentive, the Code lacked sufficient enforcement mechanisms. In particular there is no obligation on companies to report breaches of the Code to Medicines Australia, and little incentive on companies to complain about the benefits provided to doctors by their competitors.

The Tribunal made it clear that in its view pharmaceutical companies could, by providing benefits to doctors, affect prescribing decisions and thus affect patient care. The Tribunal felt that while the provision of benefits to doctors would not necessarily lead to patient harm, it was difficult to comprehend how the provision of benefits can ever be a legitimate consideration or influence in patient decision-making by that professional. Therefore, "any irrelevant consideration or influence of that kind affecting such decision-making has the potential to result in positive harm or, more likely, less than optimal treatment choices". This informed the actual reauthorisation of the Code as well as the new conditions.

The Tribunal specifically justified the conditions based on their opinion that:

"the practice of pharmaceutical companies conferring benefits upon health care professionals carries with it a risk that prescribing decisions may be affected or influenced by considerations not relevant to patient welfare. It also carries with it a risk of reduced public confidence in the industry and the profession. So far as such practises may affect prescribing decision there is a species of market failure because such influences are unrelated to product quality or patient welfare."

By mandating the provision of previously undisclosed hospitality information, the Tribunal is putting down a strong marker that the provision of "inappropriate" benefits to health professionals is a practice which is against the public interest. In its view marketing in the pharmaceutical industry must be less entertainment-based, and more education-based. In theory, this should remove inappropriate "influences" on prescribing practices.

What does the decision mean for the industry?

The decision means that the budgets of pharmaceutical companies for doctor-orientated functions, and the conferral of benefits on doctors, will be subject to public scrutiny. It is clear that the Tribunal saw this as a mechanism for enforcing the Code's existing restrictions. It commented that the current enforcement mechanisms in relation to benefits for health professionals were "weak".

It was thought that public "scrutiny of the hospitality and other benefits provided by pharmaceutical companies is more likely to lead to self imposed restraint by pharmaceutical companies then the institutional arrangements proposed by Medicines Australia."

Whether enforcement is strengthened by way of the new reporting conditions will be watched with interest.

Impact on marketing practices

The reauthorisation of the 15th Edition of the Code is a timely reason for marketing teams in member companies to audit their current marketing techniques and practices in relation to the provision of hospitality and benefits. The fact that previously confidential information will now be open to public scrutiny represents the potential for a change in marketing culture.

In practice, marketing teams must be prepared to defend marketing initiatives which they regard as legitimate and spending which they regard as reasonable. Public scrutiny will naturally be more intense and subjective. Joe Public will not think the same way as those in the industry, and teams must therefore consider carefully the likely public and media reaction to the arguments in favour of a particular initiative.

It is important to remember that the Code, for better or worse, defines acceptable marketing practices as those which are "able to withstand public and professional scrutiny and conform to professional and community standards of ethics and good taste"2 The new conditions may have the effect of making this very much a real world test.

How to prepare for the new Code?

Marketing teams may wish to look at techniques that have worked in the past, and categorise those with the greatest educational content as against cost. This provides a useful opportunity to re-visit spending and the effectiveness of certain events.

The first year of the reporting requirements will be a learning process for marketing teams as to what is a "reasonable" amount to spend on events and what "appropriate" benefits to doctors are. The Tribunal did not discuss what it believes is appropriate and so the industry is left to set its own bench-mark, bearing in mind the "public scrutiny" test explained above.

Notably, the Tribunal emphasised the importance of educating doctors at pharmaceutical company organised seminars and conferences as long as such events were truly educational. Member companies who currently adopt innovative and cost-effective educative marketing techniques will already be one step ahead. The imposition of the disclosure rules, and the need to monitor spending on such events, may lead to an increase in online education and round-table forums, as opposed to residential conferences.

Against this background, it is worth bearing in mind that the reporting conditions do not attach to:

  • general sponsorship of healthcare professional organisations
  • those instances where healthcare professional may be remunerated for their participation in advisory committees
  • direct gifts to healthcare professional which are not connected with any education event; or
  • low value items such as calendars, biros, gimmicks and mouse pads bearing the company/ product logo.

From a relationship perspective, member companies may need to provide information to doctors about the Code so they understand any changes in marketing techniques and the reasons for the withdrawal of certain more extravagant benefits.

Looking forward, the reporting conditions will increase transparency. Perhaps they provide member companies with an opportunity to demonstrate the benefits of the educational events they provide for doctors and the ways in which they put doctors in a position to make better prescribing decisions.


1 The new conditions read as follows:

"3.1 The Code of Conduct is varied within three months of this determination to include the requirement that each member company report to Medicines Australia all educational meetings and symposia as defined in ss 6, 7 and 10 of the Code held or sponsored by that company:

(a) by completing the table set out at Attachment A to the Determination for each month of the financial year;

(b) by providing a copy of the completed table for two six month periods every year (July to December, January to June) to Medicines Australia within 14 days of the end of each six month period.

3.2 The Code is further amended to provide that:

(c) Medicines Australia will make publicly available on its website the completed table provided by each member company within three months of the end of each six month period;

(d) The Monitoring Committee will, at the end of each financial year conduct a review of the information provided by the members for three months selected by it at random for the preceding 12 month period.

3.3 The Monitoring Committee will be empowered in any case to request information concerning a particular event such as a copy of the invitation to the meeting and a copy of any printed material provided to attendees.

3.4 Where the Monitoring Committee considers that the conduct of the member company with regard to the meeting may breach the Code of Conduct, it will refer a report about the meeting and the member company's response to the Code of Conduct Committee which, after giving notice to the member company, may deal with it as though it were a complaint.

3.5 The Monitoring Committee shall also provide a detailed report on its other activities to Medicines Australia for publication in the Code of Conduct Annual Report. This report shall also list any cases forwarded to the Code of Conduct Committee under the preceding provisions setting out the name of the member company and the date it was referred."

The decision requires Medicines Australia to amend the Code within three months so the disclosure rules will have immediate effect from no later than 27 September 2007.

2 See, for example, sections 6.3, 6.4, 7.1.1 and 10 of the Code


The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Mondaq Advice Centre (MACs)
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.